15104-42-4

Basic information

• Product Name: Phosphonic acid, (3-bromophenyl)-, dimethyl ester
• CAS NO: 15104-42-4
• Molecular Formula: C8H10BrO3P
• Molecular Weight: 265.043
• Mol File: 15104-42-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Phosphonic acid, (3-bromophenyl)-, dimethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Phosphonic acid, (3-bromophenyl)-, dimethyl ester(15104-42-4)
• EPA Substance Registry System: Phosphonic acid, (3-bromophenyl)-, dimethyl ester(15104-42-4)

Safety Data

• Hazardous Substances Data: 15104-42-4(Hazardous Substances Data)

Upstream product

• 591-18-4 1-Bromo-3-iodobenzene 
• 121-45-9 phosphorous acid trimethyl ester 
• 2240-41-7 dimethyl phenylphosphonate 

Relevant articles and documents

Bromination by means of sodium monobromoisocyanurate (SMBI)

A variety of aromatic compounds with both activating and deactivating substituents were brominated with sodium monobromoisocyanurate (SMBI) 1, diethyl ether, diethyl ether-methanesulfonic acid, trifluoroacetic acid, or sulfuric acid were employed as solvents. Thus nitrobenzene was conveniently brominated in sulfuric acid, benzene was readily monobrominated in diethyl ether-methanesulfonic acid, and phenol was selectively brominated at the ortho position under mild conditions in refluxing diethyl ether. With substituents that are easily protonated, trifluoroacetic acid may be employed as solvent in the reaction with 1, in contrast NBS was ineffective in trifluoroacetic acid. This renders 1 a superior reagent relative to NBS. In addition to aromatics, alkenes, ketones and esters were also brominated with 1. Diethyl malonate was brominated with 1 and then subjected to a Bingel reaction with NaH to afford the desired methanofullerene in reasonable yield.

HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE

Disclosed are compounds having the formula (I): wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.